by Rutgers University Credit: CC0 Public Domain COVID-19 saliva testing kits that include a novel preservative can also be used measure microscopic organisms in the mouth, a Rutgers study has found. This enables study of the relationship between mouth and lung microbes and the SARS-CoV-2 virus that may allow for the development of new treatments. The...
by Collene Ferguson, University of Calgary From left: Bryan Yipp, Sarthak Sinha, Jeff Biernaskie, and Nicole Rosin led the multidisciplinary study. Credit: Riley Brandt, University of Calgary A new study from the University of Calgary shows how dexamethasone, the main treatment for severe COVID-19 lung infections, alters how immune cells work, which may help male patients,...
by Beth Israel Deaconess Medical Center Credit: Pixabay/CC0 Public Domain In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19—known as CVnCoV and developed by CureVac—reported approximately 48 percent efficacy against symptomatic disease. CV2CoV is a second generation vaccine developed by CureVac with noncoding modifications to optimize the vaccine. Researchers at Beth Israel...
by Catherine Caruso, Harvard Medical School Credit: Unsplash/CC0 Public Domain For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported...
by University of Sydney Figure 2. Predicting vaccine efficacy against SARS-CoV-2 variants The association between mean neutralization of ancestral SARS-CoV-2 and protection against symptomatic (A) and severe infection (B) with different variants is shown. The line indicates the model prediction of efficacy for a given neutralization against ancestral virus. Shading indicates 95% CI based on uncertainties...
JOHNS HOPKINS MEDICINE IMAGE: ELECTRON MICROGRAPH OF A SINGLE SARS-COV-2 PARTICLE WITH ITS SPIKE PROTEINS (BLUE) CLEARLY VISIBLE. THE INSET IS A 3D MODEL OF THE SPIKE PROTEIN — THE PORTION OF THE COVID-19 VIRUS THAT CURRENTLY AVAILABLE MRNA VACCINES RECOGNIZE. A RECENT JOHNS HOPKINS MEDICINE STUDY SUGGESTS THAT T LYMPHOCYTES — IMMUNE SYSTEM CELLS...
by Bill Hathaway, Yale University Credit: Pixabay/CC0 Public Domain A simple RNA molecule jumpstarts the immune system’s “first responders” to viral infection and can even eradicate the SARS-CoV-2 virus in mice with chronic cases of COVID-19, a new Yale School of Medicine study finds. The molecule, known as SLR14, is a simple, easy to manufacture, loop...
by University of Montreal A colorized scanning electron micrograph of the SARS-CoV-2 virus. Credit: NIAID With the emergence of SARS-CoV-2 variants worldwide, the pandemic’s spread is accelerating. A research team led by Joelle Pelletier and Jean-François Masson, both professors in Université de Montréal’s Department of Chemistry, wanted to find out whether natural infection or vaccination...
by Sara Sawyer, Arturo Barbachano-Guerrero, Cody Warren, The Conversation Credit: Pixabay/CC0 Public Domain Now that kids ages 5 to 11 are eligible for COVID-19 vaccination and the number of fully vaccinated people in the U.S. is rising, many people may be wondering what the endgame is for COVID-19. Early on in the pandemic, it wasn’t unreasonable to expect that SARS-CoV-2...
AMERICAN COLLEGE OF ALLERGY, ASTHMA, AND IMMUNOLOGY NEW ORLEANS (November 5, 2021) – Studies have shown minority populations suffered higher rates of COVID-19 infections throughout the pandemic. A new study being presented at this year’s American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting reveals Latinos with asthma were 4.6 times more likely than...
